TQB2102 + penpulimab

TQB2102 + penpulimab is a combination therapy under clinical investigation for the treatment of unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. **TQB2102** is an antibody-drug conjugate (ADC) that targets the HER2 protein by binding to two non-overlapping epitopes (ECD2 and ECD4), enhancing internalization and downregulation of HER2 on tumor cells. It delivers a topoisomerase I inhibitor payload via an enzyme-cleavable linker, aiming for potent cytotoxicity against HER2-expressing cancer cells. **Penpulimab** is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor on T cells, thereby restoring T-cell-mediated anti-tumor responses and decreasing immune escape by tumor cells. Penpulimab is engineered to minimize Fc-mediated immune side effects. Together, these drugs combine targeted cytotoxicity and immune checkpoint inhibition to suppress tumor growth and improve immune-mediated clearance[1][2][7].